In the current application, PEI-PEG-RGD targeted gene carrier was synthesized and characterized. The constructed plasmid encoding sFllt-1 was carried to angiogenic dermal microvascular endothelial cells. The in vivo studies demonstrated that expressed sFlt-1 carried by this delivery system delayed tumor growth and increased survival rate of animal. Therefore, PEI-PEG-RGD/pCMV- sFlt-1 complex can be useful to develop tumor specific anti-angiogenic gene therapy. In addition, combination of IL-2 and sFlk-1 plasmid was constructed. The in vitro and in vivo studies demonstrated excellent efficiency of anti-tumor activity. In this renewal application, we propose to deliver siRNA for silencing VEGF and VEGF receptors. RGD will be conjugated to the reducible polymer, poly (CBA-DAH), which is known to be non-toxic and greatly enhances transfection in several cell lines. RGD-chol-R9C will also be synthesized, since chol-R9C has demonstrated high transfection of siRNA. In addition, RGD- PEG-water soluble lipopolymer (WSLP) will be designed as WSLP has been proven an excellent carrier in this laboratory. Extensive in vitro and in vivo animal studies will be carried out with these RGD-conjugated polymers complexed with siRNA. Inhibition of tumor growth in murine prostate and breast adenocarcinoma models will be proven in the results. The obtained data can be utilized for the design of siRNA delivery to treat cancer patients.

Public Health Relevance

Three newly designed polymers will be conjugated with RGD. It is expected that both in vitro and in vivo studies will present positive results for siRNA delivery, which can be applied to tumor treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA107070-07
Application #
7768437
Study Section
Bioengineering, Technology and Surgical Sciences Study Section (BTSS)
Program Officer
Fu, Yali
Project Start
2004-04-01
Project End
2014-01-31
Budget Start
2010-02-01
Budget End
2011-01-31
Support Year
7
Fiscal Year
2010
Total Cost
$271,181
Indirect Cost
Name
University of Utah
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Lee, Won Jai; Lee, Ju Hee; Ahn, Hyo Min et al. (2015) Heat Shock Protein 90 Inhibitor Decreases Collagen Synthesis of Keloid Fibroblasts and Attenuates the Extracellular Matrix on the Keloid Spheroid Model. Plast Reconstr Surg 136:328e-337e
Lee, Jung-Sun; Oh, Eonju; Yoo, Ji Young et al. (2015) Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells. Oncotarget 6:4051-65
Moon, Chang Yoon; Choi, Joung-Woo; Kasala, Dayananda et al. (2015) Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus. Biomaterials 41:53-68
Jung, Soo-Jung; Kasala, Dayananda; Choi, Joung-Woo et al. (2015) Safety profiles and antitumor efficacy of oncolytic adenovirus coated with bioreducible polymer in the treatment of a CAR negative tumor model. Biomacromolecules 16:87-96
Lee, Cho-Hee; Kasala, Dayananda; Na, Youjin et al. (2014) Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression. Biomaterials 35:5505-16
Lee, Young Sook; Kim, Sung Wan (2014) Bioreducible polymers for therapeutic gene delivery. J Control Release 190:424-39
Kasala, Dayananda; Choi, Joung-Woo; Kim, Sung Wan et al. (2014) Utilizing adenovirus vectors for gene delivery in cancer. Expert Opin Drug Deliv 11:379-92
Kim, J; Nam, H Y; Choi, J W et al. (2014) Efficient lung orthotopic tumor-growth suppression of oncolytic adenovirus complexed with RGD-targeted bioreducible polymer. Gene Ther 21:476-83
Kim, Hyun Ah; Nam, Kihoon; Kim, Sung Wan (2014) Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery. Biomaterials 35:7543-52
Florinas, Stelios; Kim, Jaesung; Nam, Kihoon et al. (2014) Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment. J Control Release 183:1-8

Showing the most recent 10 out of 37 publications